The company anticipates Adjusted EBITDA of $20 million to $40 million, a decrease at the midpoint of $487.6 million or 94% as compared to 2021. The company anticipates Adjusted Net Loss of $(90) million to $(70) million, compared to 2021 Adjusted Net Income of $325.7 million.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on EBS:
- EBS Bags $380 Million Contract with U.S. Army
- Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
- Emergent BioSolutions awarded $379.6M lotion contract for DoD
- Benchmark keeps Hold on Emergent after non-profit OTC naloxone competitor news
- Emergent BioSolutions: FDA accepts for review sNDA for Narcan Nasal Spray